SGO Winter Meeting | Conference

Dr. Corr on the Utilization of Molecular Profiling in Endometrial Cancer

January 26th 2022

Bradley R. Corr, MD, discusses the utilization of molecular profiling in endometrial cancer.

Combinations Will Lead the Way in Immunotherapy for Ovarian Cancer

February 11th 2020

Chemotherapy in combination with immunotherapy holds promise in the treatment paradigm for patients with ovarian cancer, Floor Backes, MD, said at the 2020 SGO Winter Meeting.

Role of PARP Inhibition Shifts in Ovarian Cancer as Research Efforts Expand

February 11th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the role of rucaparib as a treatment option for patients with ovarian cancer, how this agent compares with other PARP inhibitors in this space, and where research is headed for these agents.

Dr. Backes on Experience With PARP Inhibitors in Ovarian Cancer

February 10th 2020

Floor J. Backes, MD, discusses the role of PARP inhibitors as treatment of patients with ovarian cancer and her experience with these agents, such as rucaparib.

Dr. Secord on Financial Toxicity Associated With PARP Inhibition

February 10th 2020

Angeles Alvarez Secord, MD, discusses a presentation from the 2020 SGO Winter Meeting that focused on assistance with the financial burden associated with PARP inhibitors in patients with ovarian cancer.

Secord Shares Data to Digest With PARP Inhibitors in Ovarian Cancer

February 10th 2020

Three pivotal clinical trials evaluating PARP inhibitors have significantly impacted the treatment of patients with newly diagnosed ovarian cancer.

Dr. Hagemann on Best Practices for Pathology in Gynecologic Cancers

February 9th 2020

Ian Hagemann, MD, PhD, discusses the main take home from his presentation at the 2020 SGO Winter Meeting.

Dr. Fehniger on Expanding PARP Inhibitors to Other Gynecologic Cancers

February 9th 2020

Julia Fehniger, MD, shares her thoughts on the development of PARP inhibitors in ovarian cancer and expansion into other tumor types.

Immunotherapy Shows Promise in Cervical Cancer Treatment

February 9th 2020

With few chemotherapy options available for patients with cervical cancer, R. Wendel Naumann, MD, said that immunotherapy represents an attractive treatment option in the landscape.

Dr. Secord on the Role of PARP Inhibitors in Ovarian Cancer

February 9th 2020

Angeles Alvarez Secord, MD, gynecologic oncologist, Duke Cancer Center, discusses the role of PARP inhibitors in ovarian cancer based on their current indications in the treatment landscape.

Dr. Langstraat on Sentinel Lymph Nodes for Endometrial Cancer

February 9th 2020

Carrie L. Langstraat, MD, gynecologic oncologist, Mayo Clinic, discusses the role of sentinel lymph nodes in patients with endometrial cancers.

Novel PARP Combinations Boost Responses in Ovarian Cancer

February 9th 2020

Floor J. Backes, MD, discusses the latest advancements made in the treatment of patients with ovarian cancer and the ongoing research efforts that are being made with novel combinations.

PARP Inhibitors May Have Benefit in BRCA-Mutant Endometrial Cancers

February 8th 2020

Tumors from a significant percentage of patients with endometrial cancer at NYU Langone Health’s Perlmutter Cancer Center were found to have BRCA1/2 somatic mutations.

Treatment Options Abound in Platinum-Sensitive Ovarian Cancer

February 8th 2020

In ovarian cancer, disease that returns within 6 months of treatment following platinum-based therapy is defined as platinum-sensitive.

Targeted Therapy, Immunotherapy Are Replacing Chemotherapy in Endometrial Cancer

February 8th 2020

Researchers and practicing physicians have done as much as possible with chemotherapy as a systemic treatment for endometrial cancers, and other modalities—alone and in combination—are likely to become standard of care in the coming years, Shannon N. Westin, MD, MPH, said during a presentation at the 2020 SGO Winter Meeting.

Expert: Frontline Maintenance With PARP Inhibition Should Be Standard in Ovarian Cancer

February 7th 2020

Maintenance treatment with PARP inhibitors should be the standard of care in the frontline setting for patients with ovarian cancer, Kathleen M. Moore, MD, said during a presentation at the 2020 Society of Gynecologic Oncology Winter Meeting.

Patient Selection Key to Future of Immunotherapy in Endometrioid Disease

January 22nd 2019

Successful application of immunotherapy in endometrial cancer means identifying the patients with inflamed tumors who will respond to treatment and those who will not, and finding ways to treat noninflamed tumors with immunotherapy agents.

Ongoing Research to Move Needle Forward in Gynecologic Cancer Treatment

January 21st 2019

Robert Coleman, MD, highlights recent advances made in gynecologic cancers and provide insight into ongoing research to move the needle forward.

Dr. Leath Discusses Unmet Need in Cervical Cancer

January 20th 2019

Charles A. Leath III, MD, gyn oncologist at the University of Alabama at Birmingham, discusses the glaring unmet need in cervical cancer.

Dr. Coleman on Advances Made in Ovarian Cancer Treatment

January 20th 2019

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses advances made in the treatment of ovarian cancer.